← All trials
NCT05280873
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 10, 2021
- Primary completion
- Oct 20, 2023
- Completion date
- Oct 20, 2024
- First posted
- Mar 15, 2022
- Last posted
- Mar 15, 2022
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangzhou Medical UniversityLead sponsor
- Guangzhou Medical UniversitySponsor investigator
- Guangzhou Medical UniversityStudy director
- GNI GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.